Tag: Cycle Pharmaceuticals
-
FDA Approves Cavhanza for Philadelphia Chromosome Positive Chronic Myeloid Leukemia
When the FDA approves a new cancer treatment, it often signals a meaningful step forward for patients who need more flexible or effective options. That is exactly what happened with Cavhanza, a newly approved orally disintegrating tablet (ODT) formulation of nilotinib for adults with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML). Cavhanza is designed…